138 related articles for article (PubMed ID: 17330105)
61. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
Tvedt TH; Nepstad I; Bruserud Ø
Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095
[TBL] [Abstract][Full Text] [Related]
62. [Possibility of targeting FLT3 kinase for the treatment of leukemia].
Kiyoi H
Rinsho Ketsueki; 2005 Mar; 46(3):187-97. PubMed ID: 16447713
[No Abstract] [Full Text] [Related]
63. [FLT3 kinase inhibitors for the treatment of acute leukemia].
Kiyoi H
Rinsho Ketsueki; 2010 Jun; 51(6):384-9. PubMed ID: 20622483
[No Abstract] [Full Text] [Related]
64. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway.
Zhou J; Pan M; Xie Z; Loh SL; Bi C; Tai YC; Lilly M; Lim YP; Han JH; Glaser KB; Albert DH; Davidsen SK; Chen CS
Leukemia; 2008 Jan; 22(1):138-46. PubMed ID: 17943175
[TBL] [Abstract][Full Text] [Related]
65. The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia.
Eriksson A; Hermanson M; Wickström M; Lindhagen E; Ekholm C; Jenmalm Jensen A; Löthgren A; Lehmann F; Larsson R; Parrow V; Höglund M
Blood Cancer J; 2012 Aug; 2(8):e81. PubMed ID: 22864397
[TBL] [Abstract][Full Text] [Related]
66. Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines.
Kano Y; Akutsu M; Suzuki K; Yoshida M
Leuk Res; 1993 Feb; 17(2):113-9. PubMed ID: 8429687
[TBL] [Abstract][Full Text] [Related]
67. Inhibition of PKCalpha activation in human bone and soft tissue sarcoma cells by the selective PKC inhibitor PKC412.
Kawamoto T; Akisue T; Kishimoto K; Hara H; Imabori M; Fujimoto T; Kurosaka M; Hitora T; Kawaguchi Y; Yamamoto T
Anticancer Res; 2008; 28(2A):825-32. PubMed ID: 18507025
[TBL] [Abstract][Full Text] [Related]
68. Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines.
Takagi T; Yazawa Y; Suzuki K; Yamauchi Y; Kano Y
Invest New Drugs; 1996; 14(4):357-63. PubMed ID: 9157070
[TBL] [Abstract][Full Text] [Related]
69. Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines.
Yazawa Y; Takagi T; Asakura S; Suzuki K; Kano Y
J Orthop Sci; 1999; 4(3):231-7. PubMed ID: 10370165
[TBL] [Abstract][Full Text] [Related]
70. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C.
Virchis A; Ganeshaguru K; Hart S; Jones D; Fletcher L; Wright F; Wickremasinghe R; Man A; Csermak K; Meyer T; Fabbro D; Champain K; Yap A; Prentice HG; Mehta A
Hematol J; 2002; 3(3):131-6. PubMed ID: 12111648
[TBL] [Abstract][Full Text] [Related]
71. Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism.
Mazzarella L; Botteri E; Matthews A; Gatti E; Di Salvatore D; Bagnardi V; Breccia M; Montesinos P; Bernal T; Gil C; Ley TJ; Sanz M; Bhaskaran K; Coco FL; Pelicci PG
Haematologica; 2020 Jun; 105(6):1559-1566. PubMed ID: 31515354
[TBL] [Abstract][Full Text] [Related]
72. A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatography.
Illmer T; Thiede HM; Thiede C; Bornhäuser M; Schaich M; Schleyer E; Ehninger G
J Pharmacol Toxicol Methods; 2007; 56(1):23-7. PubMed ID: 17395497
[TBL] [Abstract][Full Text] [Related]
73. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.
Weisberg E; Roesel J; Furet P; Bold G; Imbach P; Flörsheimer A; Caravatti G; Jiang J; Manley P; Ray A; Griffin JD
Genes Cancer; 2010 Oct; 1(10):1021-32. PubMed ID: 21779428
[TBL] [Abstract][Full Text] [Related]
74. Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
Grant S; Dent P
Curr Drug Targets; 2007 Jun; 8(6):751-9. PubMed ID: 17584030
[TBL] [Abstract][Full Text] [Related]
75. Cre recombinase promotes leukemogenesis in the presence of both homozygous and heterozygous FLT3-ITD.
Yang M; Ma Z; Wang C; Agca MC; Liu H; Huang K; Glage S; Rumpel R; Gerbaulet A; Roers A; Liu X; Noyan F; von Neuhoff N; Ganser A; Liu L; Yun H; Li Z
Leukemia; 2024 Jun; 38(6):1437-1439. PubMed ID: 38720016
[No Abstract] [Full Text] [Related]
76. Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias.
Van Vlierberghe P; Meijerink JP; Stam RW; van der Smissen W; van Wering ER; Beverloo HB; Pieters R
Blood; 2005 Dec; 106(13):4414-5. PubMed ID: 16326981
[No Abstract] [Full Text] [Related]
77. Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells.
Gallala H; Winter J; Veit N; Nowak M; Perner S; Courts C; Kraus D; Janzen V; Probstmeier R
Tumour Biol; 2015 Apr; 36(4):2725-35. PubMed ID: 25487614
[TBL] [Abstract][Full Text] [Related]
78. [Novel molecularly target therapies for leukemia].
Kiyoi H
Nihon Rinsho; 2007 Jan; 65 Suppl 1():611-6. PubMed ID: 17474469
[No Abstract] [Full Text] [Related]
79. Acute leukemias in 2020: state of the art.
Cerchione C; Martinelli G
Minerva Med; 2020 Oct; 111(5):384-385. PubMed ID: 32957743
[No Abstract] [Full Text] [Related]
80. Dietary polyphenols influence antimetabolite agents: methotrexate, 6-mercaptopurine and 5-fluorouracil in leukemia cell lines.
Mahbub A; Le Maitre C; Haywood-Small S; Cross N; Jordan-Mahy N
Oncotarget; 2017 Dec; 8(62):104877-104893. PubMed ID: 29285220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
